| Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl) methacrylamide copolymer paclitaxel and gemcitabine conjugates R Zhang, J Yang, M Sima, Y Zhou, J Kopeček Proceedings of the National Academy of Sciences 111 (33), 12181-12186, 2014 | 139 | 2014 |
| Nanotechnology in retinal drug delivery S Jiang, YL Franco, Y Zhou, J Chen International journal of ophthalmology 11 (6), 1038, 2018 | 86 | 2018 |
| Selective inhibitory effect of HPMA copolymer-cyclopamine conjugate on prostate cancer stem cells Y Zhou, J Yang, J Kopeček Biomaterials 33 (6), 1863-1872, 2012 | 82 | 2012 |
| Biological rationale for the design of polymeric anti-cancer nanomedicines Y Zhou, J Kopeček Journal of drug targeting 21 (1), 1-26, 2013 | 73 | 2013 |
| HPMA copolymer-based combination therapy toxic to both prostate cancer stem/progenitor cells and differentiated cells induces durable anti-tumor effects Y Zhou, J Yang, JS Rhim, J Kopeček Journal of Controlled Release 172 (3), 946-953, 2013 | 58 | 2013 |
| Combination cytotoxicity of backbone degradable HPMA copolymer gemcitabine and platinum conjugates toward human ovarian carcinoma cells A Duangjai, K Luo, Y Zhou, J Yang, J Kopeček European Journal of Pharmaceutics and Biopharmaceutics 87 (1), 187-196, 2014 | 54 | 2014 |
| The role of MET in melanoma and melanocytic lesions Y Zhou, KY Song, A Giubellino The American journal of pathology 189 (11), 2138-2148, 2019 | 31 | 2019 |
| Combination therapy of prostate cancer with HPMA copolymer conjugates containing PI3K/mTOR inhibitor and docetaxel Y Zhou, J Yang, R Zhang, J Kopeček European journal of pharmaceutics and biopharmaceutics 89, 107-115, 2015 | 26 | 2015 |
| N‐(2‐Hydroxypropyl)methacrylamide Copolymer–Drug Conjugates for Combination Chemotherapy of Acute Myeloid Leukemia R Zhang, J Yang, Y Zhou, PJ Shami, J Kopeček Macromolecular bioscience 16 (1), 121-128, 2016 | 18 | 2016 |
| Peptide-guided delivery improves the therapeutic efficacy and safety of glucocorticoid drugs for treating acute lung injury H Guo, J Guan, X Wu, Y Wei, J Zhao, Y Zhou, F Li, HB Pang Molecular Therapy 31 (3), 875-889, 2023 | 9 | 2023 |
| Differential expression of preferentially expressed antigen in melanoma (PRAME) in testicular germ cell tumors–A comparative study with SOX17 Y Zhou, A Rothrock, P Murugan, F Li, L Bu Experimental and Molecular Pathology 126, 104761, 2022 | 7 | 2022 |
| Needle tract seeding in renal tumor biopsies: experience from a single institution Y Zhou, P Murugan, F Li, L Bu Diagnostic Pathology 16, 1-9, 2021 | 7 | 2021 |
| Gene expression and mutational profile in BAP-1 inactivated melanocytic lesions of progressive malignancy from a patient with multiple lesions Y Zhou, AC Nelson, Y He, SA Munro, KY Song, E Domingo-Musibay, ... Genes 13 (1), 10, 2021 | 4 | 2021 |
| Cancer stem cells: Potential target for anti-cancer nanomedicines Y Zhou, J Yang, J Kopeček Tailored polymer architectures for pharmaceutical and biomedical …, 2013 | 4 | 2013 |
| Molecular Characterization of Spitz Tumors: An Approach to Improve Disease Diagnosis and Classification A Giubellino, Y Zhou Molecular and Genetic Medicine 13 (2), 2019 | 3 | 2019 |
| Malignant Melanoma: From Molecular Characterization to Targeted Therapies EF Naharro, Y Zhou, A Giubellino Comprehensive Pharmacology, 194-210, 2022 | 2 | 2022 |
| Gene Expression Profile of Benign, Intermediate, and Malignant Spitz and Spitzoid Melanocytic Lesions A Giubellino, Y He, SA Munro, Y Zhou, KY Song, JA Plaza, ... Cancers 16 (10), 1798, 2024 | | 2024 |
| 43154 Prognostic and predictive value of MACC1 and the Met receptor tyrosine kinase in cutaneous melanoma C Rasner, Y Zhou, A Giubellino Journal of the American Academy of Dermatology 89 (3), AB77, 2023 | | 2023 |
| MACC1 and MET as markers associated with progression and metastasis in cutaneous melanoma Y Zhou, CJ Rasner, A Giubellino Frontiers in Oncology 13, 1146092, 2023 | | 2023 |
| Recurrent Nevus Phenomenon Developing within a Keloid CJ Rasner, Y Zhou, A Giubellino Dermatopathology 10 (3), 201-206, 2023 | | 2023 |
Jindrich KopecekDistinguished Professor of Biomedical Engineering, and of Pharmaceutical Chemistry在 utah.edu 的电子邮件经过验证
Jindrich KopecekDistinguished Professor of Biomedical Engineering, and of Pharmaceutical Chemistry在 utah.edu 的电子邮件经过验证